PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 6, 2026ALPHA PSYCHIATRY0 citationsOpen Access

Effects of Deep Transcranial Magnetic Stimulation on Cognitive Function in Bipolar Depression: A Randomized Controlled Trial Using the MATRICS Consensus Cognitive Battery

LCLijun ChuXJXiaoju JiaPGPing Gao

Key Points

  • This research aimed to evaluate the cognitive effects and clinical efficacy of dTMS in patients with bipolar disorder.
  • Conducted a randomized, double-blind, sham-controlled trial
  • Included 100 inpatients with bipolar disorder
  • Administered 4 weeks of active or sham H1-coil dTMS
  • Utilized the MATRICS Consensus Cognitive Battery and Hamilton Depression Rating Scale for assessments
  • Both active and sham dTMS groups showed significant cognitive improvements across most domains
  • Active dTMS group had lower HDRS-17 scores and a higher response rate compared to sham group
  • Response rate was 50% for active dTMS vs. 24% for sham, indicating a significant difference
  • All treatments displayed a favorable safety profile with mild side effects

Abstract

Background: Bipolar disorder (BD) is characterized by persistent cognitive deficits. These deficits contribute to functional impairment and often respond poorly to pharmacotherapy. Although deep transcranial magnetic stimulation (dTMS) has demonstrated antidepressant efficacy, there is limited knowledge about its cognitive effects and comprehensive clinical performance in BD. In this study, we assessed the cognitive outcomes, clinical efficacy, and safety of H1-coil dTMS in BD patients. Methods: In this randomized, double-blind, sham-controlled trial, 100 inpatients with BD received 4 weeks of active or sham H1-coil dTMS. The MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) Consensus Cognitive Battery (MCCB) was used to investigate the cognitive function, and the 17-item Hamilton Depression Rating Scale (HDRS-17) was used to assess depressive symptoms from baseline to week 4. Results: Both groups, active and sham dTMS, showed significant cognitive improvements across most domains (p 0.05). At the endpoint, the active dTMS group showed statistically significantly lower HDRS-17 scores and a higher response rate than the sham group (mean difference = 2.94, 95% CI 0.10, 5.78, p = 0.04); 50% vs. 24%; OR = 3.17, 95% CI 1.35, 7.44, p = 0.007). All treatments demonstrated a favorable safety profile, with only mild and transient adverse effects. Conclusions: In patients with BD, active dTMS was well-tolerated and was associated with a higher response rate and statistically significant (albeit modest) lower depressive symptom scores compared to sham stimulation, without inducing cognitive adverse effects. However, no specific cognitive benefit beyond its antidepressant effect was established. Overall, these results indicate that dTMS has potential as an adjunctive treatment option for bipolar depression, particularly when medications are limited or poorly tolerated. Clinical Trial Registration: NCT06524505. Registered 23 July, 2024, https://clinicaltrials.gov/study/NCT06524505.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Chu et al. (2026) studied this question.

synapsesocial.com/papers/69aa7048531e4c4a9ff59e56https://doi.org/10.31083/ap47409
Ask AI
Helpful
Bookmark
Share
View Full Paper